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Introduction
Breast cancer is the most common cancer amongst females and the second leading cause of cancer-related deaths in females. Over 1 million women are diagnosed and more than 400 000 women die from breast cancer every year (1) . Mounting evidences indicate that induction of the neoplastic phenotype is invoked for the early events leading to increased tumorigenicity and metastasis. Thus, it is of great clinical value to identify potential early biomarkers to improve the diagnosis and prognostic assessment of breast cancer.
Golgi phosphoprotein 3 (GOLPH3), also known as GPP34, is a newly identified membrane protein in the trans-Golgi matrix, which plays a role in anterograde and retrograde Golgi trafficking (2) (3) (4) . Recently, GOLPH3 has been shown to be involved in tumorigenesis.
GOLPH3 localizes in human chromosome 5p13, a region that is frequently amplified in multiple solid tumor types (5) (6) (7) . It has been reported that overexpression of GOLPH3 promotes cell transformation via enhancing the activity of the serine/threonine kinase mammalian target of rapamycin (mTOR) (8, 9) . GOLPH3 overexpression also drived the transformation of primary cell lines and enhances mouse xenograft tumor growth in vivo. In contrast, silencing of GOLPH3 expression abrogates the transformation and proliferation of tumor cell lines in which GOLPH3 is amplified (9, 10) . The clinical significance and biological role of GOLPH3 in breast cancer, however, remains largely unknown.
In this study, we found that GOLPH3 expression was significantly upregulated in breast cancer cells and tissues, and was associated with the clinical features of breast cancer.
Furthermore, we demonstrated that GOLPH3 can promote proliferation and tumorigenicity in breast cancer cells in vitro and in vivo. Moreover, the biological behavior of GOLPH3 was mechanistically associated with suppression of FOXO1 transcriptional activity, via activation of the AKT signaling pathway. Our results demonstrate that GOLPH3 functions as an oncoprotein in breast cancer progression, and may provide a new therapeutic target for the treatment of 
Materials and methods
Cell lines. Human mammary epithelial cells (HMECs) were established according to a previous report (11) . Breast cancer cell lines, including MDA-MB-231, MDA-MB-415, T47D, MCF-10a, BT474, MCF-7, and Bcap37 were cultured in DMEM medium (Gibco, Grand Island, NY, USA) supplemented with 10% FBS (HyClone, Logan, UT, USA).
Vectors and retroviral infection. An GOLPH3 expression construct was generated by subcloning PCR-amplified full-length human GOLPH3 cDNA into the pMSCV plasmid. For depletion of GOLPH3, two human GOLPH3-targeting siRNA sequences were cloned into pSuper-retro-puro to generate pSuper-retro-GOLPH3-RNAi(s), respectively, and the sequences are RNAi#1: GCATGTTAAGGAAACTCAGCC; RNAi#2: GCAGCGCCTCATCAAGAAAG T (synthesized by Invitrogen). Retroviral production and infection were performed as previously described (12) . Stable cell lines expressing GOLPH3 or GOLPH3 shRNAs were selected for 10 days with 0.5 μg/ml puromycin. The reporter plasmid for quantitatively detecting the transcriptional activity of FOXO1 was generated in the pGL3-Enhancer plasmid (Promega, Madison, WI, USA) as described previously (13 Immunohistochemistry (IHC). The IHC procedure and the scores of GOLPH3 expression were performed as previously reported (14) . IHC staining was quantitatively analyzed with the Axio Vision Rel.4.6 computerized image analysis system assisted with the automatic measurement program (Carl Zeiss, Oberkochen, Germany). Briefly, the stained sections were evaluated at 200× magnification and ten representative staining fields of each section, contains more than 95% tumor cells, were analyzed to verify the mean optical density (MOD), which represented the strength of staining signals as measured per positive pixel. The MOD data were statistically analyzed using the t -test to compare the average MOD difference between different groups of tissues; p < 0.05 was considered significant.
Western blotting. Western blotting was carried out according to standard methods as described previously (11), by using anti-GOLPH3, anti-p16
Ink4A , anti-p21
anti-FOXO3α, anti-p-FOXO4, anti-FOXO4, anti-P84, anti-EF-1α antibodies (Cell Signaling, Danvers, MA, USA). The membranes were stripped and re-probed with an anti-α-tubulin mouse monoclonal antibody (Sigma, Saint Louis, MI, USA) as a loading control.
MTT assay. Cells were seeded in 96-well plates at initial density of 2×10 3 /well. At each time point, cells were stained with 100 μl sterile MTT (3-(4,5-Dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide) dye (0.5 mg/ml, Sigma) for 4 hours at 37 , followed by removal of the culture medium and addition of 100 μl of dimethyl sulphoxide (Sigma, Saint
Louis, MI, USA). The absorbance was measured at 570 nm, with 655 nm as the reference wavelength. All experiments were carried out in triplicates.
Anchorage-independent growth ability assay. Five hundred cells were trypsinized and suspended in 2 ml complete medium plus 0.3% agar (Sigma, Saint Louis, MI, USA). The
Research. were plotted by the Kaplan-Meier method and compared by using the log-rank test. Survival data were evaluated by using univariate and multivariate Cox regression analyses. A p-value of less than 0.05 was considered statistically significant in all cases.
Research. 
Results

GOLPH3 is upregulated in human breast cancer cells and tissues
Real-time PCR and western blotting analysis showed that GOLPH3 mRNA and protein expression were significantly upregulated in all 7 tested breast cancer cell lines, compared to normal cells (HMECs; Fig.1A and Supplemental Fig. S1A) . Furthermore, comparative analysis revealed that the expression levels of GOLPH3 in six pairs of human breast cancer tissues were higher than those in matched adjacent non-tumor tissues (Figs.1A-1B and Supplemental Fig. S1B ). These results suggest that GOLPH3 expression is upregulated in breast cancer.
GOLPH3 expression is associated with the clinical features of breast cancer
In order to investigate the relationship between GOLPH3 expression and the clinical features Tables 2 and 3) .
Moreover, Kaplan-Meier survival curves and the log-rank test Survival analysis showed that the overall survival of patients with high levels of GOLPH3 was significantly poorer than patients with low levels of GOLPH3 (p<0.001) (Fig. 1D) . Additionally, similar results were Table 4 ), suggesting that GOLPH3 may be a prognostic factor for survival in breast cancer patients.
GOLPH3 promotes the proliferation of breast cancer cells
Striking, we found that the areas in breast cancer specimens that displayed high levels of GOLPH3 staining and also showed strong Ki67 staining signals, and areas with low GOLPH3 expression displayed weakly detectable Ki67 expression (Supplemental Fig. S4 ). Statistical analyses indicated that the expression of GOLPH3 was strongly associated with the expression level of Ki67 (p<0.001) (Supplemental Table 2 and 3), suggesting that GOLPH3 overexpression may contribute to the proliferation of breast cancer cells.
To further investigate the effect of GOLPH3 on proliferation, MCF-7 and MDA-MB-231 breast cancer cells stably overexpressing ectopic GOLPH3 were established ( Fig. 2A) . As shown in Fig.2B , the proliferation rate was significantly increased in GOLPH3 overexpressing MCF-7 and MDA-MB-231 cells, compared to control cells. These results were further confirmed by colony formation assay (Fig.2C) . Furthermore, we found that silecing GOLPH3 also significantly reduced cell proliferation that analyzed by MTT and colony formation assays ( Fig.2A, 2B and 2D) . Collectively, our results suggest that overexpression of GOLPH3 plays important roles in proliferation of breast cancer cells in vitro.
GOLPH3 promotes the tumorigenicity of breast cancer cells in vitro and in vivo
The anchorage-independent growth assay revealed that overexpressing GOLPH3 significantly increased, but silencing GOLPH3 decreased the anchorage-independent growth ability of MCF-7 and MDA-MB-231 cells in soft agar (Fig. 3A and 3B 
further examined whether GOLPH3 could promote the tumorigenicity of breast cancer cells in vivo. As shown in Fig.3C , GOLPH3-transduced tumors grew significantly faster than the control tumors at each different time point (p<0.001), whereas the tumors formed by GOLPH3-silenced cells grew much slower than control tumors (p<0.001). The tumors formed by GOLPH3-transduced breast cancer cells were larger and had higher tumor weights than vector-control tumors. Conversely, tumors formed by GOLPH3-silenced cells were smaller, in both size and weight, than the tumors formed from shRNA-vector control cells (Fig.   3C , left and right panels). Importantly, IHC assay showed that areas of strong GOLPH3 signals displayed intense cyclin D1 and Ki67 staining, whereas areas with low levels of GOLPH3 expression exhibited lower cyclin D1 and Ki67 staining signals (Supplemental Fig.   S5 ), further supporting the notion that GOLPH3 promotes the proliferation and tumorigenicity of breast cancer cells.
GOLPH3 regulates the G1-S phase transition in breast cancer cells
To further investigate the mechanism of GOLPH3 mediated-proliferation, the BrdU incorporation and flow-cytometry assays were performed. As shown in Fig.4A Fig. 4B and 4D ). Taken together, these results suggest that GOLPH3 contributes to the G1-S phase transition in breast cancer cells.
Importantly, we found that the expression levels of p21 Cip1 , p27 Kip1 levels of cyclin D1 and phospho-Rb, compared to control cells ( Fig. 5A and 5C ).
Consistently, the expression of p21
Cip1 , p27 Kip1 and p57 kip2 were significantly increased, whereas cyclin D1 and phospho-Rb decreased, in GOLPH3 silenced cells ( Fig. 5B and 5C ).
However, GOLPH3 has no effects on the expression of p16 Ink4A , cyclin A and cyclin E. (Fig.   5C ).
GOLPH3 downregulates FOXO1 transactivity and activates AKT signaling pathway
It has been reported that p21 Cip1 , p27 Kip1 , p57 kip2 and cyclin D1 are regulated by the transcriptional factor FOXO1 (16, 17) . We then examined the effect of GOLPH3 on the regulation of FOXO1 transactivity. As shown in Fig. 6A, FOXO1 reporter activity was significantly decreased in GOLPH3 overexpressing cells and significantly increased in GOLPH3 silenced cells. Importantly, we did not observed significant alterations of estrogen receptor activity and NF-κB reporter activity in GOLPH3 transduced-and GOLPH3 silenced-cells (Supplemental Fig.S6A ), further suggesting the specific effect of GOLPH3 on the FOXO1 transactivity .
As FOXO1 is a downstream target of the PI3K/AKT signaling pathway (18, 19) , the protein levels of phospho-AKT and phospho-FOXO1 were analyzed. As shown in Fig. 6B , the levels of phospho-AKT and phospho-FOXO1 were increased in GOLPH3 overexpressing cells and decreased in GOLPH3 silenced cells. However, the expression levels of phospho-FOXO3a and FOXO4 were only slightly increased in GOLPH3-transduced cells and decreased in GOLPH3-silenced cells (Supplemental Fig.S6B ). As expected, the cellular fractionation experiment showed that FOXO1 expression in the nuclei was markedly decreased in GOLPH3-transduced cells and increased in GOLPH3-silenced cells (Supplemental Fig.S6C ).
Moreover, ChIP assay indicated no physical binding of GOLPH3 to FOXO1 promoter regions (Supplemental Fig.S6D ). Taken together, these data suggest that GOLPH3 may promote the To further determine the role of FOXO1 in GOLPH3-mediated cell proliferation, we silenced the expression of FOXO1 in GOLPH3-silenced cells. As expected, the luciferase activity of the FOXO1 reporter was dramatically decreased in GOLPH3 silenced cells after FOXO1 siRNA(s) transfection (Supplemental Fig. S7A ). Combined knockdown of FOXO1 in GOLPH3 silenced cells decreased the expression of p21
Cip1 , p27 Kip1 , and p57 kip2 , but increased the cyclin D1 expression (Supplemental Fig. S7B and S7C) . Moreover, colony formation and MTT assays showed that silencing of FOXO1 restored the growth rate of GOLPH3-silenced MCF-7 and MDA-MB-231 cells ( Fig. 6C and 6D ). Collectively, our results suggest that FOXO1 plays an important role in the effect of GOLPH3 on proliferation in breast cancer cells.
Discussion
The key findings of this study are that GOLPH3 overexpression was significantly associated with progression of human breast cancer, and that ectopic expression of GOLPH3 increased the proliferation and tumorigenicity of breast cancer cells. We demonstrated that GOLPH3 promotes cell proliferation by accelerating the G1-S phase transition through downregulation of FOXO1 transcriptional activity via activation of AKT signaling pathway. This study provides new insights and strong evidences that GOLPH3 overexpression plays important roles in promoting the tumorigenicity and progression of human breast cancer.
Tumorigenesis is a complex multi-step process, characterized by uncontrolled cell growth and tumor formation, is largely associated with progressive accumulation of genetic and various epigenetic alterations in genes or proteins that regulate cell proliferation (20, 21) . Therefore, identification of the genes and their products that lead to tumorigenesis is critical for providing new diagnostic and prognostic methods and potential therapeutic targets.
Previously, it has been reported that GOLPH3 is amplified at the 5p13 region in several types of cancer, including breast cancer (9) . The clinical significance and biological role of GOLPH3 in breast cancer progression, however, remains largely unknown. Herein, we found that GOLPH3 was significantly upregulated in a large cohort of human breast cancer tissues, and that GOLPH3 levels significantly correlated with the clinical characteristics of breast cancer, including the clinical stage, TNM classification, and expression of ER and Ki67.
Importantly, survival analysis demonstrated that patients with low GOLPH3 expression have better overall survival compared to patients with high levels of GOLPH3, suggesting that GOLPH3 is a predictor for breast cancer patient survival. proliferation, differentiation, stress responses and apoptosis through transcriptional induction of the CDK inhibitors, including p21
Cip1 , p27 Kip1 and p57 Kip2 (22) (23) (24) . Indeed, deregulation of FOXO1 expression is observed in multiple cancers, including breast cancer, prostate cancer, chronic myelogenous leukemia, glioblastoma, rhabdomyosarcoma and leukemia (24) (25) (26) (27) (28) (29) . In the present study, we found that FOXO1 transactivity was decreased in GOLPH3 transduced cells and enhanced in GOLPH3 silenced cells, suggesting that GOLPH3-induced proliferation and tumorigenesis may be due to modulation of FOXO1 activity. Upregulation of GOLPH3 accelerated the G1-S phase transition; whereas downregulation of GOLPH3 induced G1-S phase arrest. Furthermore, we demonstrated that the mechanism of GOLPH3-mediated proliferation was linked to alternations in the expression of the cell cycle inhibitors p21 Cip1 , p27 Kip1 and p57 Kip2 as well as the CDK regulator cyclin D1.
AKT is a serine/threonine protein kinase that plays key roles in multiple cellular processes, such as cell proliferation, apoptosis, transcription, cell migration and glucose metabolism. It has been demonstrated that phosphorylation of FOXO at Ser256 by AKT leads to the nuclear/cytoplasmic translocation and subsequent degradation of FOXO1 via the ubiquitin-proteasome system (18, 19) . Our study demonstrates that the levels of phospho-AKT and phospho-FOXO1 increased in GOLPH3 overexpressing cells and decreased in GOLPH3 silenced cells. The mechanism by which GOLPH3 activates the AKT signaling pathway is under investigation in our laboratory currently.
Metastases have already disseminated to adjacent lymph nodes or distant organs at the time of diagnosis in most breast cancer patients (31). It has been reported that GOLPH3 connects the Golgi membranes to actin cytoskeleton through binding to myosin MYO18A (32).
MYO18A, a novel p21-activated kinase PAK2-binding partner, has been proven to play an 
